FDA has authority over the formulation, manufacturing, labeling, marketing, promotion and import and export of OTC drugs in the US, and the Consumer Product Safety Commission also sets rules for them. This 90-minute OTC drug regulation training covers what you need to develop and sell an OTC product.
You'll compare the four pathways to market: following a drug monograph, an approved NDA, the Rx-to-OTC switch process, or an ANDA citing an approved product. You'll also learn how to navigate a monograph, judge ingredient safety categories and tell a potential Rx product from an OTC drug.
The session covers claims, cGMPs, tamper evidence and poison control, compliant labels, branded and generic products, and marketing strategies that limit enforcement risk.
WHY SHOULD YOU ATTEND?
OTC products face both FDA and CPSC requirements, and missteps in pathway, labeling or promotion can lead to enforcement action. This session explains your options and how to reduce that risk, including market differences between Rx and OTC products.
It suits regulatory, compliance, quality, marketing, product, labeling, R&D and document control staff, plus senior managers and business owners.
AREA COVERED
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC monograph pathways
- Rx-to-OTC switches
- cGMPs for OTC drugs
- Tamper evidence and poison control
- Branded innovator, branded generic and generic products
- FDA and CPSC requirements for OTC drugs
- Required elements of a compliant OTC label
- Ingredient safety categories and when to rely on proposed or final rules
- Marketing, promotion and reducing enforcement risk
LEARNING OBJECTIVES
- Explain how OTC drug products are regulated in the US
- Tell a potential Rx product from an OTC drug
- Compare the pathways for commercializing an OTC drug
- Navigate an OTC drug monograph and assess ingredient categories
- Identify the required elements of a compliant OTC label
- Describe the Rx-to-OTC switch process
- Market and promote OTC products while limiting enforcement risk
WHO WILL BENEFIT?
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
OTC products face both FDA and CPSC requirements, and missteps in pathway, labeling or promotion can lead to enforcement action. This session explains your options and how to reduce that risk, including market differences between Rx and OTC products.
It suits regulatory, compliance, quality, marketing, product, labeling, R&D and document control staff, plus senior managers and business owners.
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC monograph pathways
- Rx-to-OTC switches
- cGMPs for OTC drugs
- Tamper evidence and poison control
- Branded innovator, branded generic and generic products
- FDA and CPSC requirements for OTC drugs
- Required elements of a compliant OTC label
- Ingredient safety categories and when to rely on proposed or final rules
- Marketing, promotion and reducing enforcement risk
- Explain how OTC drug products are regulated in the US
- Tell a potential Rx product from an OTC drug
- Compare the pathways for commercializing an OTC drug
- Navigate an OTC drug monograph and assess ingredient categories
- Identify the required elements of a compliant OTC label
- Describe the Rx-to-OTC switch process
- Market and promote OTC products while limiting enforcement risk
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
Speaker Profile
Dr. Loren Gelber
Dr. Loren Gelber has worked in the pharmaceutical industry for more than 40 years, at both the FDA and in private industry. She has prepared more than 50 submissions to the FDA. Her specialty is compliance with US regulatory requirements. She has a BA in Biology, an MS in Chemistry and a Ph.D. in Medicinal Chemistry.
Upcoming Webinars
Medical Device Cybersecurity Following FDA’s 2026 Premarket…
Managing Toxic Employees: Strategies For Leaders To Effecti…
California Meal and Rest Breaks: What You Don't Know Can Co…
Human Error Reduction Techniques for Floor Supervisors
Unlock Employee Loyalty: Stay Interviews Will Keep Them Eng…
Performance of Root Cause Analysis, CAPA, and Effectiveness…
Your AI Advantage: How HR Professionals Can Use Claude to S…
The Anti-Kickback Statute: Enforcement and Recent Updates
Empowering Conflict Resolution: Letting Go to Gain Control
Wage & Hour Laws: Ensuring Compliance with the Fair Labor S…
Using Copilot to Format Legal Documents in Microsoft Word
Dealing With Difficult People: At Work & In Life
Using Stay Interviews To Improve Employee Retention & Engag…
AI in Word - Smarter Writing and Document Creation with Cha…
FDA Current Trends in Compliance and Enforcement for FDA-Re…
Zero Acceptance Sampling to Reduce Inspection Costs
Why EBITDA Doesn't Spell Cash Flow and What Does?
Mastering Tough Conversations: Turn Conflict into Clarity, …
Enhancing Pivot Tables with Images: Visualize Your Data Lik…
Discover how Emotional Intelligence turns AI from a technic…
Understanding Financial Statements for Non-Financial Profes…
SOPs - How to Write Them to Satisfy those Inspectors
Managing Projects When AI Joins the Team: Human Judgment, A…